A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
暂无分享,去创建一个
Myeong Jun Song | J. Jang | S. Bae | S. Yoon | H. Woo | J. Choi | H. Lee | Bohyun Jang | H. Chun | J. Oh | Hyun Yang | H. Nam | S. Lee | D. Song | J. Han | S. Lee | Angelo Lozada | Ji Won Han | J. Han
[1] Myeong Jun Song,et al. Comparative Study between Metronomic Chemotherapy and Transarterial Chemoembolization in Patients with Child-Pugh Class B Advanced Hepatocellular Carcinoma , 2015 .
[2] P. Hoff,et al. Safety and efficacy of sorafenib in patients with Child-Pugh B advanced hepatocellular carcinoma. , 2015, Molecular and clinical oncology.
[3] J. Heo,et al. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis , 2015, Clinical and molecular hepatology.
[4] D. Sinn,et al. Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors. , 2015, Journal of hepatology.
[5] I. Song,et al. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions , 2015, BMC Cancer.
[6] Myeong Jun Song,et al. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis , 2015, Journal of Gastroenterology.
[7] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[8] G. Brandi,et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. , 2013, The oncologist.
[9] H. Koga,et al. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. , 2013, Translational oncology.
[10] N. Vu,et al. Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties , 2013, Cytotechnology.
[11] J. Jang,et al. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis , 2012, The Korean journal of hepatology.
[12] Chih-Hung Hsu,et al. Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma , 2012, Oncology.
[13] H. Chang,et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function , 2011, Cancer Chemotherapy and Pharmacology.
[14] S. Bae,et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma , 2010, The Korean journal of hepatology.
[15] Nicolas André,et al. Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.
[16] Chih-Hung Hsu,et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. , 2010, Journal of Hepatology.
[17] W. Hur,et al. Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis , 2010, Cancer Chemotherapy and Pharmacology.
[18] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[19] P. Malfertheiner,et al. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer , 2009, Journal of Cancer Research and Clinical Oncology.
[20] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[21] J. Jang,et al. Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma , 2004, Cancer Chemotherapy and Pharmacology.
[22] A. Burroughs,et al. Hepatocellular carcinoma , 2003, The Lancet.
[23] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[24] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[25] S. Bae,et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma , 2009, Cancer Chemotherapy and Pharmacology.
[26] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.